Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02637934 · ClinicalTrials.gov registry record · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
A Phase 1 study of Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT02637934: Recruiting Phase 1 study of Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02637934 is a Phase 1 study of Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 35 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02637934, a Phase 1 study of Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
Up to 40 evaluable women with known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer will participate in two different imaging cohorts. The Biodistribution cohort will include up to 4 patients and the Dynamic cohort will include up to 36 patients. Human dosimetry will be calculated from the Biodistribution cohort. The Dynamic cohort date will evaluate preliminary information on uptake of \[18F\]FTT in gynecological cancer and compare with PARP-1 activity in tissue.
Conditions Studied
Interventions
- DRUG [18F]FluorThanatrace
- RADIATION PET/CT imaging sessions
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2016-01-14 |
| Est. Completion | 2026-01 |
| Phase | Phase 1 |
What NCT02637934 shows while recruiting
NCT02637934 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer appearing as the primary indexed condition, and to 2 interventions - of which [18F]FluorThanatrace is the first listed.
NCT02637934 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02637934 about?
NCT02637934 is a clinical study titled "Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT". Up to 40 evaluable women with known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer will participate in two different imaging cohorts. The Biodistribution cohort will include up to 4 patients and the Dynamic cohort will include up to 36 patients. Human dosimetry will be...
What is the current status of trial NCT02637934?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2016-01-14. Estimated completion is 2026-01.
What conditions does trial NCT02637934 study?
This clinical trial studies the following conditions: Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
What interventions are being tested in trial NCT02637934?
The interventions under investigation include: [18F]FluorThanatrace (DRUG), PET/CT imaging sessions (RADIATION).
Who is sponsoring clinical trial NCT02637934?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02637934 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02637934's enrollment target sits among peer trials
35 1259th of 2000 higher than 728 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT03167437 · 35 participants · Phase 1
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI